MXPA05011293A - Medicamento para la terapia perioperativa de dos etapas de tumores solidos. - Google Patents
Medicamento para la terapia perioperativa de dos etapas de tumores solidos.Info
- Publication number
- MXPA05011293A MXPA05011293A MXPA05011293A MXPA05011293A MXPA05011293A MX PA05011293 A MXPA05011293 A MX PA05011293A MX PA05011293 A MXPA05011293 A MX PA05011293A MX PA05011293 A MXPA05011293 A MX PA05011293A MX PA05011293 A MXPA05011293 A MX PA05011293A
- Authority
- MX
- Mexico
- Prior art keywords
- solid tumours
- medicament
- agent
- therapy
- perioperative therapy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 230000001093 anti-cancer Effects 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 1
- 230000004807 localization Effects 0.000 abstract 1
- 230000010415 tropism Effects 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Abstract
La presente invencion describe el uso de un agente dotado con tropismo tumoral en combinacion con otro agente con actividad anticancerosa y con una afinidad para el primer agente para la preparacion de un medicamento util para la terapia perioperativa de dos etapas de tumores solidos. Las ventajas de la presente invencion consisten en la localizacion mayor, efectiva de su actividad anticancerosa, en la reduccion del numero de etapas de administracion y en la posibilidad de reducir las dosis anticancerosas, con una disminucion resultante en efectos colaterales, pero sin ninguna perdida de eficacia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000196A ITRM20030196A1 (it) | 2003-04-24 | 2003-04-24 | Uso di reagenti per la preparazione di un medicamento |
| PCT/IT2004/000184 WO2004093916A1 (en) | 2003-04-24 | 2004-04-07 | A medicament for the two-step perioperative therapy of solid tumours |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05011293A true MXPA05011293A (es) | 2006-01-24 |
Family
ID=29765781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05011293A MXPA05011293A (es) | 2003-04-24 | 2004-04-07 | Medicamento para la terapia perioperativa de dos etapas de tumores solidos. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7935346B2 (es) |
| EP (1) | EP1615668B1 (es) |
| JP (1) | JP4949016B2 (es) |
| KR (1) | KR20060005383A (es) |
| CN (1) | CN1777446A (es) |
| AR (1) | AR044052A1 (es) |
| AU (1) | AU2004231377B2 (es) |
| BR (1) | BRPI0409604A (es) |
| CA (1) | CA2522580C (es) |
| CY (1) | CY1113488T1 (es) |
| DK (1) | DK1615668T3 (es) |
| ES (1) | ES2398389T3 (es) |
| HR (1) | HRP20121052T8 (es) |
| IT (1) | ITRM20030196A1 (es) |
| MX (1) | MXPA05011293A (es) |
| PL (1) | PL1615668T3 (es) |
| PT (1) | PT1615668E (es) |
| SI (1) | SI1615668T1 (es) |
| TW (1) | TWI368518B (es) |
| WO (1) | WO2004093916A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030196A1 (it) | 2003-04-24 | 2004-10-25 | Sigma Tau Ind Farmaceuti | Uso di reagenti per la preparazione di un medicamento |
| CN101772353B (zh) * | 2007-08-02 | 2013-03-06 | 希格马托制药工业公司 | 在受治疗组织中展现高停留时间的氧化的抗生物素蛋白 |
| IT1398977B1 (it) | 2009-06-25 | 2013-03-28 | Icgeb | Agente anticancro specifico per i tumori cerebrali con meccanismo di soppressione di recq1 |
| CN103717239B (zh) * | 2011-08-02 | 2017-08-01 | 希格马托制药工业公司 | 适合于吸入的氧化抗生物素蛋白的药物组合物 |
| WO2015112636A1 (en) * | 2014-01-21 | 2015-07-30 | The Trustees Of Columbia University In The City Of New York | Compositions for radiotherapy and uses thereof |
| US10925852B2 (en) * | 2015-06-30 | 2021-02-23 | The Trustees Of Columbia University In The City Of New York | Talc-bound compositions and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| IT1245748B (it) * | 1990-12-21 | 1994-10-14 | Mini Ricerca Scient Tecnolog | Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego |
| US6096289A (en) * | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| JPH09506594A (ja) | 1993-12-07 | 1997-06-30 | ネオルクス コーポレーション | プレターゲティング方法及び化合物 |
| ITRM20010079A1 (it) * | 2001-02-16 | 2002-08-16 | Sigma Tau Ind Farmaceuti | Amminoderivati della biotina e loro coniugati con chelanti macrociclici. |
| JP2004538269A (ja) * | 2001-06-11 | 2004-12-24 | ユニバーシティー オブ マイアミ | 移植寛容を達成することにおける放射性医薬品複合体の使用 |
| ITRM20020071A1 (it) * | 2002-02-11 | 2003-08-11 | Sigma Tau Ind Farmaceuti | Contenitore per flacone di radiofarmaco, e corredo per la sua infusione in un paziente o per il suo trasferimento altrove. |
| US20030228256A1 (en) * | 2002-06-11 | 2003-12-11 | Inverardi Luca A. | Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations |
| ITRM20030196A1 (it) | 2003-04-24 | 2004-10-25 | Sigma Tau Ind Farmaceuti | Uso di reagenti per la preparazione di un medicamento |
-
2003
- 2003-04-24 IT IT000196A patent/ITRM20030196A1/it unknown
-
2004
- 2004-04-07 KR KR1020057019995A patent/KR20060005383A/ko not_active Ceased
- 2004-04-07 MX MXPA05011293A patent/MXPA05011293A/es active IP Right Grant
- 2004-04-07 PL PL04726249T patent/PL1615668T3/pl unknown
- 2004-04-07 CN CNA200480010867XA patent/CN1777446A/zh active Pending
- 2004-04-07 BR BRPI0409604-5A patent/BRPI0409604A/pt not_active IP Right Cessation
- 2004-04-07 EP EP04726249A patent/EP1615668B1/en not_active Expired - Lifetime
- 2004-04-07 PT PT47262498T patent/PT1615668E/pt unknown
- 2004-04-07 CA CA2522580A patent/CA2522580C/en not_active Expired - Fee Related
- 2004-04-07 AU AU2004231377A patent/AU2004231377B2/en not_active Ceased
- 2004-04-07 DK DK04726249.8T patent/DK1615668T3/da active
- 2004-04-07 ES ES04726249T patent/ES2398389T3/es not_active Expired - Lifetime
- 2004-04-07 HR HRP20121052TT patent/HRP20121052T8/hr unknown
- 2004-04-07 JP JP2006507647A patent/JP4949016B2/ja not_active Expired - Fee Related
- 2004-04-07 WO PCT/IT2004/000184 patent/WO2004093916A1/en not_active Ceased
- 2004-04-07 SI SI200431974T patent/SI1615668T1/sl unknown
- 2004-04-07 US US10/554,410 patent/US7935346B2/en not_active Expired - Fee Related
- 2004-04-12 TW TW093110125A patent/TWI368518B/zh not_active IP Right Cessation
- 2004-04-22 AR ARP040101356A patent/AR044052A1/es not_active Application Discontinuation
-
2012
- 2012-12-14 CY CY20121101221T patent/CY1113488T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL1615668T3 (pl) | 2013-03-29 |
| DK1615668T3 (da) | 2013-02-04 |
| CA2522580A1 (en) | 2004-11-04 |
| US7935346B2 (en) | 2011-05-03 |
| TWI368518B (en) | 2012-07-21 |
| ITRM20030196A1 (it) | 2004-10-25 |
| CY1113488T1 (el) | 2016-06-22 |
| US20060251579A1 (en) | 2006-11-09 |
| JP2006524235A (ja) | 2006-10-26 |
| KR20060005383A (ko) | 2006-01-17 |
| AU2004231377B2 (en) | 2010-08-05 |
| CN1777446A (zh) | 2006-05-24 |
| WO2004093916A1 (en) | 2004-11-04 |
| CA2522580C (en) | 2013-08-06 |
| HRP20121052T8 (en) | 2013-03-31 |
| SI1615668T1 (sl) | 2013-01-31 |
| WO2004093916A8 (en) | 2005-11-03 |
| TW200501984A (en) | 2005-01-16 |
| EP1615668A1 (en) | 2006-01-18 |
| EP1615668B1 (en) | 2012-12-05 |
| PT1615668E (pt) | 2013-01-14 |
| HRP20121052T1 (hr) | 2013-01-31 |
| ES2398389T3 (es) | 2013-03-15 |
| ITRM20030196A0 (it) | 2003-04-24 |
| BRPI0409604A (pt) | 2006-04-18 |
| JP4949016B2 (ja) | 2012-06-06 |
| AU2004231377A1 (en) | 2004-11-04 |
| AR044052A1 (es) | 2005-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273765A (en) | Combinations and forms of administration of therapeutic agents and combined treatment | |
| WO2007084670A3 (en) | Specific therapy using integrin ligands for treating cancer | |
| WO2000006134A3 (en) | Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity | |
| WO2005070930A3 (en) | Tetrahydrocarboline compounds as anticancer agents | |
| WO2009010287A3 (en) | Specific therapy and medicament using integrin ligands for treating cancer | |
| IL155781A0 (en) | Effective antitumor treatments | |
| WO2009140675A3 (en) | Combination therapy with pm00104 and another antitumor agent | |
| WO2010136168A3 (en) | Continuous administration of cilengitide in cancer treatments | |
| WO2006043083A3 (en) | Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy | |
| WO2005118601A3 (en) | Sulfonylethyl phosphorodiamidates for use in the treatment of cancer | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| WO2018102261A3 (en) | Boronic derivatives hydroxamates as anticancer agents | |
| CY1113488T1 (el) | Ενα φαρμακο για την δυο βαθμιδων περιεγχειρητικη θεραπεια συμπαγων ογκων δια ραδιοανοσοθεραπειας | |
| WO2005076888A3 (en) | Anti-cancer therapies | |
| WO2007082742A8 (en) | Isolated organ perfusion combination therapy of cancer | |
| WO2010057596A3 (en) | New therapy and medicament using integrin ligands for treating cancer | |
| WO2003072061A3 (en) | Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy | |
| EP1374873B8 (en) | The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy | |
| WO2006124573A3 (en) | Treatment of cancer with 2-deoxyglucose | |
| WO2006043031A3 (en) | Class iii slrp for the treatment of cancer | |
| WO2007047489A3 (en) | Compositions and methods for use in cancer therapy | |
| SG153877A1 (en) | Treatment of cancer | |
| TNSN06454A1 (en) | Treatment of cancer | |
| HK1123212A (en) | Fixed ratio drug combination treatments for solid tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |